A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Status:
Terminated
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of
PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizimab sourced
from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese
participants with advanced non-squamous NSCLC in the first-line treatment setting.